Tag: TOTUM-070

VALBIOTIS Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

The first subject, with blood LDL-cholesterol (“bad cholesterol”) levels greater than 130 mg/dL, has undergone the initial medical examination for the HEART protocol on the active substance TOTUM-070. The HEART study will include 120 people with elevated blood LDL-cholesterol, a risk factor for cardiovascular disease and the primary endpoint of […]

VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia

TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor; Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications; A milestone in the further development of TOTUM-070, in the search for commercial partnerships […]

VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/ SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the acceleration of its pipeline clinical development, of plant-derived active substances, in new indications: cardiovascular and hepatic steatosis risk. Building […]